GOV.UK: MHRA welcomes sentencing after fraud convictions over falsely certified medical devices

• GOV.UK - Fraud news states Medicina Limited and Harrison were found guilty of fraud offences relating to P900 enteral feeding pumps, gastrostomy button devices and blunt fill needle devices on 1 July 2026.
• GOV.UK confirms Harrison was disqualified from being a company director for eight years and ordered to complete 175 hours of community service.

Kenneth George Harrison was sentenced at Manchester Crown Court on 23 September 2026 after being found guilty of fraud offences involving falsely certified medical devices supplied to hospitals across the UK. The sentence includes a three-year prison term suspended for three years, 175 hours of community service, 10 days of rehabilitation, and an eight-year disqualification from being a company director.

The MHRA’s Devices Compliance Unit led a decade-long investigation, first identifying concerns in 2013. The investigation revealed that devices, including enteral feeding pumps and gastrostomy button devices, were supplied with invalid CE markings, resulting in false assurances of safety. Confiscation proceedings under the Proceeds of Crime Act have commenced to recover funds from the criminal activity.

• 175 hours Community service ordered

• Review supply chain for P900 enteral feeding pumps, gastrostomy button devices and blunt fill needle devices linked to Medicina Limited.
• Verify CE and UKCA markings on medical devices as required by MHRA regulations.
• Monitor MHRA safety alerts and recalls related to enteral feeding pumps used in neonatal intensive care units.

This case highlights the importance of verifying the authenticity of regulatory certifications on medical devices, as fraudulent markings can lead to unsafe products entering the healthcare system. Compliance officers must ensure robust due diligence and monitoring of suppliers, especially for devices used in critical care settings. The MHRA’s enforcement actions and ongoing confiscation proceedings demonstrate the regulatory consequences of non-compliance and the need for vigilance against fraud in medical device supply chains.